Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey [Corrigendum]

Innocenti R, Rigacci L, Restelli U, et al. J Blood Med. 2019;10:21–27.

On page 24, Figure 2, the key for the figure was incorrect. The corrected figure:

Figure 2.

Kaplan–Meier plot of percentage of patients with bone marrow recovery at the time (days) of G-CSF discontinuation (lenograstim or filgrastim).

Abbreviation: G-CSF, granulocyte-colony stimulating factor.